Navigation Links
ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
Date:5/29/2008

- Phase 3 Study in 681 Stem Cell Transplant Patients Represents First Pivotal Study on a New Antiviral CMV Therapy in Stem Cell Transplant in

Over a Decade - - Company Also Provides Timing of Phase 3 Data Disclosure and Regulatory

Submissions -

EXTON, Pa., May 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients. This international Phase 3 study is evaluating the efficacy, safety and tolerability of prophylactic use of maribavir administered orally for up to 12 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT). The study also will evaluate the pharmacokinetics of maribavir in this subject population. It is being conducted in 90 transplant centers in the U.S., Canada, and Europe.

"Maribavir may mark the first new advancement in CMV therapeutics for transplant recipients in many years," stated Stephen Villano, M.D., vice president, clinical research and development at ViroPharma. "CMV can cause significant and potentially deadly clinical manifestations among transplant recipients, and maribavir represents the opportunity for a shift in CMV treatment paradigm toward prophylaxis against CMV, thus preventing CMV viral infection and disease and allowing for enhanced focus on other aspects of patient outcome following transplantation."

The company also provided the timing of future milestones in the development of maribavir in SCT. These include:

-- Data collection for the 6-month assessments will continue through the

end of November 2008;<
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Discontinuation of HCV-796 Development
2. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Present at the Natixis Bleichroeder Conference
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. Genmab Announces Updates on Phase III Cancer Studies
10. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
11. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. ... for the treatment of cancer, announces that Kareg ... , has issued the following research report on  ... Traube , Director of Research, Kareg Corporation, Initiating ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... Calif. , July 14, 2014 /PRNewswire/ ... announces a technology partnership with global bioengineering ... its technology for quick-to-market products. ... and DNA2.0,s machine learning optimization technologies, such ... up the process of engineering proteins in ...
(Date:7/14/2014)... Ltd. (NASDAQ: SVA ), a leading provider of biopharmaceutical products ... its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at ... Shangdi Xi Road, Haidian District, Beijing , PRC. All ... vote and are invited to attend. The primary agenda of ... Yuk Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3
(Date:7/14/2014)... July 14, 2014 BCC Research ... SYNTHETIC BIOLOGY: GLOBAL MARKETS , the global ... nearly $11.9 billion in 2018, with a five-year ... products account for the fastest growing segment, with ... Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, energy, ...
(Date:7/14/2014)... The Encino cosmetic dentist at Encino ... and porcelain veneers. These restorations are an excellent alternative ... greater loss of healthy tooth tissue. They work similarly ... on the tooth. Encino dentist Dr. Mastour and his ... they offer the most appropriate treatment recommendations for each ...
(Date:7/14/2014)... Gray HealthDay Reporter ... suggests that a faltering sense of smell might signal ... inexpensive, low-tech smell test could spot who needs more ... the decreased ability to identify odors was associated with ... Alzheimer,s disease. "We,re trying to be able to ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
Breaking Medicine News(10 mins):Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3
... hunger strike to protest against the raising of the Narmada ... attending on her Sunday. // ,"Medha Patkar has ... doctor at the All India Institute of Medical Sciences (AIIMS) ... ,AIIMS medical superintendent D.K. Sharma said that Patkar's ...
... strapped for cash are planning on letting go of staff and ... Hospital in Wolverhampton, a hospital in such a crisis which has ... hoping to save about ?2.5 million a year. The management hope ... medical secretary bill by sending voice recordings over the internet to ...
... a Melbourne study australians go to hospitals with injuiries due ... latest issue of the Medical// Journal of Australia. ... to falls of all hospital cases. ,Associate Professor ... Centre led the study and incorporated a falls prevention ...
... diet can influence corrective behaviour in prisoners.// ... product of poor nutrition was tested in a prison ... less violent when put on a diet rich in ... paper titled “Seafood Consumption and Homicide Mortality”, raised this ...
... UK has fallen to its lowest levels since such records ... Suicide Prevention Strategy. The report also shows //a drop in ... well as a decline in the number of suicides among ... major cause of preventable death in England and elsewhere. At ...
... chemicals that could trigger inflammation leading to deterioration of ... the crucial link between obesity and heart disease. ... that fat cells lying close to blood vessels in ... influence biological processes within the body, reported the online ...
Cached Medicine News:
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
Medicine Products: